Core Viewpoint - North Chip Life successfully listed on the A-share market, becoming the first medical device company to do so under the fifth standard of the Science and Technology Innovation Board, with a market value exceeding 20 billion yuan shortly after its IPO [4][21]. Company Overview - Founded by overseas PhD Song Liang in 2015, North Chip Life focuses on coronary artery disease, peripheral vascular disease, and atrial fibrillation, aiming to reduce reliance on imported products in China [5][10]. - The company has developed China's first domestically approved 60MHz high-definition intravascular ultrasound (IVUS) product and the first domestically approved FFR measurement system, filling significant gaps in the market [10][12]. Market Performance - North Chip Life's IVUS system achieved the highest market share among domestic products, while its FFR system captured 30.6% of the domestic market within a year of launch [12][16]. - The company reported revenues of approximately 92 million yuan in 2022, growing to about 184 million yuan in 2023, and projected to reach around 317 million yuan in 2024, maintaining a gross margin above 63% [16]. Investment and Support - The company has received substantial backing from various investors, including Sequoia China and Qiming Venture Partners, which have supported multiple funding rounds [7][18]. - The long-term support from investors has been crucial for North Chip Life's development, allowing it to navigate the high-risk, high-investment landscape of innovative medical device development [19][20]. Product Development - North Chip Life has launched 11 products to date, with 6 more in development, covering five major product categories including IVUS systems and FFR systems [15]. - The company emphasizes the importance of understanding clinical needs and market demands in its product innovation strategy, leading to significant breakthroughs in technology [11][16].

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712) has been listed on the Sci-Tech Innovation Board, raising nearly 1 billion yuan through the issuance of 57 million shares at a price of 17.52 yuan per share [1] Group 1: Financial Performance - The opening price of North Chip Life was 50.31 yuan, representing a 187% increase from the issuance price, with a market capitalization of 20.871 billion yuan at midday [3] - The company expects annual revenue between 520 million and 560 million yuan, reflecting a growth of 64.24% to 76.88% year-on-year [7] - Revenue for the first nine months of 2025 reached 407 million yuan, a 71.36% increase from 240 million yuan in the same period last year [7] - The projected net profit for the company in 2025 is between 78 million and 88 million yuan, indicating a year-on-year growth of 278.91% to 301.85% [7] Group 2: Company Overview - North Chip Life was established in 2015, focusing on cardiac interventional diagnostics, primarily developing, producing, and selling interventional and implantable medical devices [5] - The company’s FFR measurement system consists of the TruePhysio pressure microcatheter and the VivoCardio FFR measurement device, which aids in precise diagnosis and treatment of coronary artery disease [5] - The company reported revenues of 92.45 million yuan, 184 million yuan, and 317 million yuan for the years 2022, 2023, and 2024, respectively, with net losses of 300 million yuan, 155 million yuan, and 53.74 million yuan for the same years [5] Group 3: Shareholder Structure - Major investors include Sequoia Capital, Tiger Med, Qiming Venture Partners, and others, with Sequoia being the largest institutional shareholder [8] - Prior to the IPO, the actual controller, Song Liang, held 16.1530% of the shares directly and controlled an additional 13.414% through employee stock ownership platforms, totaling 29.5670% [8] - Post-IPO, Song Liang's direct shareholding decreased to 14.5377%, while Sequoia Capital's shareholding was reduced to 9.1583% [12][13]

Core Insights - The article highlights the significant role of Beixin Life in the cardiovascular precision intervention solutions industry in China, emphasizing its pioneering efforts in promoting domestic clinical precision diagnosis for coronary artery diseases [2]. Company Overview - Beixin Life's initial public offering (IPO) price is set at 17.52 yuan, with a total market capitalization of 7.306 billion yuan [2]. - The company has a subscription rate of 0.03% for its IPO inquiry [2]. Business Highlights - Beixin Life is recognized as an industry leader in providing cardiovascular precision intervention solutions, being the first to innovate in this field within China [2]. - The core product, the FFR measurement system, captured a 30.6% market share in domestic indications in 2021, ranking second in the domestic market with a 10.4% overall market share [2]. - The company has a rich product pipeline with seven ongoing research projects aimed at iterative upgrades, including a radiofrequency ablation system that has entered the clinical trial phase [2]. - The controlling shareholder, Dr. Song Liang, possesses over 18 years of relevant research and development experience, and the core products have received awards for technological advancement and recognition as excellent domestic products [2].

Core Viewpoint - North Chip Life Technology Co., Ltd. is preparing for an IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board, focusing on innovative medical devices for cardiovascular disease diagnosis and treatment, amidst significant competition and past financial losses [2][5][8]. Group 1: Company Overview - North Chip Life was established in 2015 and has undergone multiple rounds of financing, with a valuation increase from 54 million RMB in the Pre-A round to 5.043 billion RMB in the D round, representing over a 90-fold growth in five years [3][4]. - The company has transitioned from a limited company to a joint-stock company and previously attempted to list on the Hong Kong Stock Exchange before shifting focus to the Sci-Tech Innovation Board [2][5]. Group 2: Financial Performance - Over the past three years, North Chip Life reported cumulative losses of approximately 474 million RMB, with revenues of 92.45 million RMB, 184 million RMB, and 317 million RMB for 2022, 2023, and projected for 2024, respectively [15][17]. - The company has high sales expenses, which were 82.08%, 55.98%, and 34.61% of revenue in the respective years, significantly higher than industry averages [19][21]. Group 3: Market Position and Products - North Chip Life's core products include the IVUS diagnostic system and the FFR measurement system, both of which are the first domestically developed products approved by the National Medical Products Administration [9][13]. - The projected market share for the IVUS system is 10.6% and for the FFR system is 29.5% by 2024, with major competitors like Boston Scientific and Philips holding 65.8% and 15.6% market shares, respectively [10][12]. Group 4: Challenges and Risks - The company faces significant pressure to complete a successful IPO by December 31, 2024, or it may have to buy back shares from investors under a contractual agreement [6][8]. - North Chip Life has experienced a decline in R&D personnel, which could impact its innovation capabilities, especially as it relies heavily on technological advancements in the competitive medical device sector [25][28].

Group 1 - The core product of the company is the IVUS (Intravascular Ultrasound) system, which is expected to see a sales price decrease of 24%-32% after the implementation of centralized procurement in 2024, but the sales volume is projected to grow rapidly [1][2] - The company anticipates that the sales volume and revenue from the IVUS system will increase by 204.6% and 108.4% respectively in 2024 compared to 2023, despite the significant drop in sales price [2] - The company reported revenues of 92.45 million yuan, 184 million yuan, and 316.6 million yuan for the years 2022, 2023, and 2024 respectively, with net losses of 300.4 million yuan, 155.2 million yuan, and 53.74 million yuan during the same period [2][3] Group 2 - The company's sales expenses were 75.88 million yuan, 102.99 million yuan, and 109.58 million yuan for the years 2022, 2023, and 2024, accounting for 82.08%, 55.98%, and 34.61% of total revenue respectively [3] - Despite a decreasing trend in the proportion of sales expenses to revenue, the company's sales expense ratio remains significantly higher than the average of comparable companies, which was 26.04% and 23.25% for 2022 and 2023 respectively [3] - The IVUS market is becoming increasingly competitive with the entry of domestic companies such as Hengyu Medical and Kaili Medical, alongside multinational corporations like Boston Scientific and Philips [3]